Pembrolizumab-Induced Acalculous Cholecystitis Mimicking Gallbladder Carcinoma on 18 F-FDG PET/CT.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40611463.
- Also identified by DOI 10.1097/RLU.0000000000005905.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lung cancer is one of the most common causes of cancer-related deaths. Immune checkpoint inhibitors (ICIs) have improved the survival of patients with metastatic lung cancer. But, by activating the immune system, they can lead to immune-mediated adverse events. Here we report a case of metastatic lung adenocarcinoma presenting with right upper abdominal pain after initiation of pembrolizumab. 18 F-FDG PET/CT highlighted the FDG avid thickening in the ICI-induced acalculous cholecystitis mimicking carcinoma gall bladder, which was confirmed on FNAC from the thickening and follow-up PET/CT imaging.
Medical subject headings
- Acalculous Cholecystitis
- Antibodies, Monoclonal, Humanized
- Fluorodeoxyglucose F18
- Gallbladder Neoplasms
- Positron Emission Tomography Computed Tomography